Found 52 hits of Enzyme Inhibition Constant Data
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 70nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 70nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 120nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 160nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 260nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 270nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 270nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 350nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 600nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 650nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 700nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 770nMAssay Description:Inhibition of urokinase (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 1.30E+3nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2.10E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2.30E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2.40E+3nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2.50E+3nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2.80E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3.30E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3.30E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3.60E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3.70E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 4.00E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 4.80E+3nMAssay Description:Inhibition of FD-mediated alternative complementation pathway in 50% human whole blood assessed as reduction in zymosan-induced membrane-attack compl...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 4.80E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 5.20E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 6.50E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 7.70E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 8.09E+3nMAssay Description:Inhibition of F11a (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 8.20E+3nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 8.70E+3nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 1.36E+4nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2.10E+4nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of urokinase (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3.20E+4nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair
TargetTryptase beta-2(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 5.50E+4nMAssay Description:Inhibition of tryptase-beta2 (unknown origin)More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 6.40E+4nMAssay Description:Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...More data for this Ligand-Target Pair